Manage Account
Change Password
Sign Out
UserName
Profession Email
Profession Email
|
Dosage/Direction for Use
Oral Gastro-oesophageal reflux disease, Irritable bowel syndrome, Dyspepsia Adult: 25 mg tid. Elderly: Dose reductions may be necessary. |
|
Contraindications
Phaeochromocytoma, epilepsy, manic states, hyperprolactinaemia, mammary dysplasia, malignant mastopathies, cardiac impairment. GI bleeding, mechanical obstruction or perforation.
|
|
Special Precautions
May impair ability to drive or operate machinery. Pregnancy and lactation.
|
|
Adverse Reactions
Amenorrhoea, gynaecomastia, galactorrhoea, changes in libido.
Potentially Fatal: Neuroleptic malignant syndrome. |
|
Drug Interactions
Reduced bioavailability with sucralfate, aluminium- and magnesium-containing antacids. Effect on GI motility may be antagonised by anticholinergic agents, narcotics and analgesics. Avoid alcohol.
|
|
Action
Levosulpiride is a substituted benzamide, which exerts antidopaminergic (selective dopamine D2 receptors) activity on both central and peripheral levels. It is an atypical neuroleptic and a prokinetic agent.
Absorption: Oral bioavailability is about 30%; peak plasma concentrations after about 3 hr. Excretion: Mainly via urine. Plasma half-life: 9.7 hr (oral); 4.3 hr (IV). |
|
Storage
Oral: Store at 15-30°C (59-86°F).
|
|
ATC Classification
N05AL07 - levosulpiride ; Belongs to the class of benzamides antipsychotics.
|
